Characterisation of receptors for IGF-I and insulin; evidence for hybrid insulin/IGF-I receptor in human coronary artery endothelial cells

Growth Hormone and IGF Research

Volumn 16, Issue 4, 2006, Pages 258-266

  Chisalita, Simona I ^a   Nitert, Marloes Dekker ^a   Arnqvist, Hans J ^a  

^a Diabetes Research Centre   (Sweden)

Author keywords

Human endothelial cells; Insulin; Insulin like growth factor I

Indexed keywords

DNA; INSULIN; INSULIN GLARGINE; INSULIN RECEPTOR; IODINE 125; MONOCLONAL ANTIBODY; RECEPTOR PROTEIN; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ARTERY ENDOTHELIUM; ARTICLE; BETA CHAIN; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DISEASE; DNA SYNTHESIS; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LIGAND BINDING; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; RECEPTOR AFFINITY; RECEPTOR BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

BLOTTING, WESTERN; CELLS, CULTURED; CORONARY VESSELS; DNA; ENDOTHELIAL CELLS; HUMANS; IMMUNOPRECIPITATION; INSULIN; INSULIN-LIKE GROWTH FACTOR I; MUTANT CHIMERIC PROTEINS; PROTEIN BINDING; RADIOLIGAND ASSAY; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYMIDINE;

EID: 33748169659     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2006.06.003     Document Type: Article

References (52)

1. Haffner S.M. Coronary heart disease in patients with diabetes. N. Engl. J. Med. 342 14 (2000) 1040-1042
2. Stamler J., Vaccaro O., Neaton J., and Wentworth D. For the MRFIT research group, diabetes, other risk factors, and cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 16 (1993) 434-444
3. Nesto R.W. The relation of insulin resistance syndromes to risk of cardiovascular disease. Res. Cardiovasc. Med. 4 Suppl 6 (2003) S11-S18
4. Cines D.B., Pollak E.S., Buck C.A., et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 91 (1998) 3527-3561
5. Biegelsen E.S., and Loscalzo J. Endothelial function and atherosclerosis. Coron. Artery Dis. 10 (1999) 241-256
6. Stehouwer C.D., Lambert J., Donker A.J., and van Hinsbergh V.W. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc. Res. 34 (1997) 55-68
7. Bonetti P.O., Lerman L.O., and Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler. Throm. Vasc. Biol. 23 (2003) 168-175
8. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362 (1993) 801-809
9. Stolar M.W., and Chilton R.J. Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. Clin. Ther. 25 Suppl B (2003) B4-B31
10. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 48 (1999) 937-942
11. Haffner S.M. Epidemiology of insulin resistance and its relation to coronary artery disease. Am. J. Cardiol. 84 (1999) 11J-14J
12. Juul A., Scheike T., Davidsen M., Gyllenborg J., and Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 106 (2002) 939-944
13. Frystyk J., Ledet T., Moller N., Flyvbjerg A., and Ørskov H. Cardiovascular disease and insulin-like growth factor 1. Circulation 106 (2002) 893-895
14. Saltiel A.R., and Kahn C.R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414 6865 (2001) 799-806
15. Dupont J., and LeRoith D. Insulin and insulin-like growth factor I receptors: similarities and differences in signal transduction. Horm. Res. 55 Suppl 2 (2001) 22-26
16. Ullrich A., Bell J.R., Chen E.Y., Herrera R., et al. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 313 (1985) 756-761
17. Ullrich A., Gray A., Tam A.W., Yang-Feng T., et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 5 (1986) 2503-2512
18. Rechler M.M., and Nissley S.P. The nature and regulation of the receptors for insulin-like growth factors. Annu. Rev. Physiol. 47 (1985) 425-442
19. Bailyes E.M., Nave B.T., Soos M.A., Orr S.R., Hayward A.C., and Siddle K. Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting. Biochem. J. 327 Pt 1 (1997) 209-215
20. Federici M., Porzio O., Zucaro L., Fusco A., Borboni P., Lauro D., and Sesti G. Distribution of insulin/insulin-like growth factor-I hybrid receptors in human tissues. Mol. Cell. Endocrinol. 129 2 (1997) 121-126
21. Moxham C.P., Duronio V., and Jacobs S. Insulin-like growth factor I receptor beta-subunit heterogeneity. Evidence for hybrid tetramers composed of insulin-like growth factor I and insulin receptor heterodimers. J. Biol. Chem. 264 (1989) 13238-13244
22. Soos M.A., Field C.E., and Siddle K. Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity. Biochem. J. 290 (1993) 419-426
23. Langlois W.J., Sasaoka T., Yip C.C., and Olefsky J.M. Functional characterization of hybrid receptors composed of a truncated insulin receptor and wild type insulin-like growth factor 1 or insulin receptors. Endocrinology 136 5 (1995) 1978-1986
24. Seely B.L., Reichart D.R., Takata Y., Yip C., and Olefsky J.M. A functional assessment of insulin/insulin-like growth factor-I hybrid receptors. Endocrinology 136 4 (1995) 1635-1641
25. Sesti G., Federici M., Lauro D., Sbraccia P., and Lauro R. Molecular mechanism of insulin resistance in type 2 diabetes mellitus: role of the insulin receptor variant forms. Diabetes Metab. Res. Rev. 17 5 (2001) 363-373
26. Pandini G., Frasca F., Mineo R., Sciacca L., Vigneri R., and Belfiore A. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J. Biol. Chem. 277 (2002) 39684-39695
27. Chisalita S.I., and Arnqvist H.J. Insulin-like growth factor-I receptors are more abundant than insulin receptors in human micro-and macrovascular endothelial cells. Am. J. Physiol. Endocrinol. Metab. 286 6 (2004) E896-E901
28. Ohashi H., Rosen K.M., Smith F.E., Komaroff V.-L., Nayak R.C., and King G.L. Characterization of type I IGF receptor and IGF-I mRNA expression in cultured human and bovine glomerular cells. Regul. Pept. 4 (1993) 9-20
29. Spoerri P.E., Ellis E.A., Tarnuzzer R.W., and Grant M.B. Insulin-like growth factor: receptor and binding proteins in human retinal endothelial cell cultures of diabetic and non-diabetic origin. Growth. Horm. IGF Res. 8 (1998) 125-132
30. Kurtzhals P., Schaffer L., Sorensen A., Kristensen C., Jonassen I., Schmid C., and Trub T. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49 (2000) 999-1005
31. Bar R.S., Hoak J.C., and Peacock M.L. Insulin receptors in human endothelial cells: identification and characterization. J. Clin. Endocrinol. Metab. 47 (1978) 699-702
32. Bar R.S., Peacock M.L., Spanheimer R.G., Veenstra R., and Hoak J.C. Differential binding of insulin to human arterial and venous endothelial cells in primary culture. Diabetes 29 (1980) 991-995
33. Zeng G., and Quon M.J. Insulin-stimulated production of nitric oxide is inhibited by wortmannin, direct measurement in vascular endothelial cells. J. Clin. Invest. 98 (1996) 894-898
34. Federici M., Menghini R., Mauriello A., et al. Insulin-dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosylation modification of signaling proteins in human coronary endothelial cells. Circulation 106 (2002) 466-472
35. Pandini G., Vigneri R., Costantino A., et al. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signalling. Clin. Cancer. Res. 5 7 (1999) 1935-1944
36. Frystyk J., Skjærbæk C., Dinesen B., and Ørskov H. Free insulin-like growth factors (IGF-I and IGF-II) in human serum. FEBS Lett. 348 (1994) 185-191
37. Chen J.W., Ledet T., and Orskov H. A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum. Am. J. Physiol. Endocrinol. Metab. 284 6 (2003) E1149-E1155
38. Aljada A., Ghanim H., Assian E., and Dandona P. Tumor necrosis factor-alpha inhibits insulin-induced increase in endothelial nitric oxide synthase and reduces insulin receptor content and phosphorylation in human aortic endothelial cells. Metabolism 51 (2002) 487-491
39. Boute N., Pernet K., and Issad T. Monitoring the activation state of the insulin receptor using bioluminescence resonance energy transfer. Mol. Pharmacol. 60 4 (2001) 640-645
40. Entingh-Pearsall A., and Kahn C.R. Differential Roles of the Insulin and Insulin-like Growth Factor-I Receptors in Response to Insulin and IGF-I. J. Biol. Chem. 279 (2004) 38016-38024
41. Sakai K., and R Clemmons D. Glucosamine induces resistance to insulin-like growth factor I (IGF-I) and insulin in Hep G2 cell cultures: biological significance of IGF-I/insulin hybrid receptors. Endocrinology 144 6 (2003) 2388-2395
42. Federici M., Zucaro L., Porzio O., Massoud R., Borboni P., Lauro D., and Sesti G. Increased expression of insulin/insulin-like growth factor-I hybrid receptors in skeletal muscle of noninsulin-dependent diabetes mellitus subjects. J. Clin. Invest. 98 12 (1996) 2887-2893
43. Valensise H., Liu Y.Y., Federici M., Lauro D., Dell'anna D., Romanini C., and Sesti G. Increased expression of low-affinity insulin receptor isoform and insulin/insulin-like growth factor-I hybrid receptors in term placenta from insulin-resistant women with gestational hypertension. Diabetologia 39 8 (1996) 952-960
44. Staiger K., Staiger H., Schweitzer M.A., Metzinger E., Balletshofer B., Häring H.-U., and Kellerer M. Insulin and its analogue glargine do not affect viability and proliferation of human coronary artery endothelial and smooth muscle cells. Diabetologia 48 9 (2005) 1898-1905
45. King G.L., Buzney S.M., Kahn C.R., Hetu N., Buchwald S., Macdonald S.G., and Rand L.I. Differential responsiveness to insulin of endothelial and support cells from micro-and macrovessels. Clin. Invest. 71 4 (1983) 974-979
46. Hanaire-Broutin H., Sallerin-Caute B., and Poncet M.F. Insulin therapy and GH-IGF-I axis disorders in diabetes: impact of glycaemic control and hepatic insulinization. Diabetes Metab 22 (1996) 245-250
47. Ekman B., Nystrom F., and Arnqvist H.J. Circulating IGF-I concentrations are low and not correlated to glycaemic control in adults with type 1 diabetes. Eur. J. Endocrinol. 143 (2000) 505-510
48. Landin-Wilhelmsen K., Wilhelmsen L., Lappas G., et al. Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin. Endocrinol. (Oxf.) 41 (1994) 351-357
49. Rosen T., and Bengtsson B.A. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336 (1990) 285-288B
50. Bulow B., Hagmar L., Eskilsson J., et al. Hypopituitary females have a high incidence of cardiovascular morbidity and an increased prevalence of cardiovascular risk factors. J. Clin. Endocrinol. Metab. 85 (2000) 574-584
51. Harrela M., Qiao Q., Koistinen R., et al. High serum insulin-like growth factor binding protein-1 is associated with increased cardiovascular mortality in elderly men. Horm. Metab. Res. 34 (2002) 144-149
52. Laughlin G.A., Barrett-Connor E., Criqui M.H., and Kritz-Silverstein D. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J. Clin. Endocrinol. Metab. 89 1 (2004) 114-120